Last reviewed · How we verify
intranasal povidone-iodine
At a glance
| Generic name | intranasal povidone-iodine |
|---|---|
| Also known as | PROFEND |
| Sponsor | University of Iowa |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study) (PHASE4)
- Nasal Antisepsis for C. Auris Prevention (PHASE4)
- Mupirocin-Iodophor ICU Decolonization Swap Out Trial (PHASE4)
- Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery (NA)
- Effect of Local Treatment(Carrageenan Nasal Spray and PVP-I Mouthwash) in Reducing Viral Load in Patients With COVID-19 (PHASE4)
- Nasal Decolonization of Dialysis Patients Noses (PHASE4)
- Nasal Decolonization for Orthopedic Trauma Patients (PHASE4)
- COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intranasal povidone-iodine CI brief — competitive landscape report
- intranasal povidone-iodine updates RSS · CI watch RSS
- University of Iowa portfolio CI